Physician profile
Mark A Terry
NPI 1760498737
$104,124.18
in general payments reported to CMS, 2019-2025
9 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $10K · 2021: $21K · 2022: $8,043 · 2023: $12K · 2024: $11K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $37K · Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $37,232.87 |
| Food and Beverage | $291.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46,070.75 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $45,181.64 | 2022-2025 | Ophthalmic Instruments |
| Moria INC | $10,000.00 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $1,286.95 | 2019 | |
| W. L. Gore & Associates, INC. | $1,200.00 | 2019 | |
| Alcon Vision LLC | $123.73 | 2024 | Clareon |
| Oyster Point Pharma, INC. | $93.84 | 2022 | |
| Biotissue Holdings INC. | $90.42 | 2025 | |
| Glaukos Corporation | $76.85 | 2023-2024 | Ce-Marked Kxla System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.